The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
EMIS: Merchant Securities raises target from 900p to 1,050p, buy rating kept.
Numis downgrades EMIS Group from add to hold, target price raised from 770p to 900p.
EMIS Group Sell 04-Sep-12 £7,000,000.00 Phillip Woodrow 1,000,000 @ 700.00p
1.3 mill buy/sell...?..
EMIS Group: Merchant Securities raises target from 700p to 800p, buy rating kept; N+1 Brewin downgrades to hold, 680p target maintained; Numis downgrades to add, target lifted from 745p to 770p.
EMIS, which supplies software to doctors' surgeries and pharmacies, has reported a slight drop in market share but revenues and profits are growing strongly. By the end of the first half of 2012 52.2% of general practitioners (GPs) had EMIS systems installed for maintaining patient records, down from the 53.1% reported at the end of 2011. On the financial front, though, results have been impressive with revenue growing 19% on the prior year to hit £42.3m and adjusted operating profit up 15% to £11.5m. Profit before tax climbed from £10.2m to £12.1m. The interim dividend has been announced at 7.1p per share, up 15% on 2011. The shares had gained 3% by 11:03 and have now doubled in value since the initial flotation back in 2010.
Sean Riddell, Chief Executive of EMIS Group, said: "So far 2012 has been another busy year for EMIS Group. We have accelerated the roll-out to GPs of EMIS Web, our transformational healthcare system, whilst RX Systems continues to grow its market share. The outlook for the remainder of the financial year is encouraging and we continue to be positive about the Group's prospects. "We are delighted to be an integral part of what the Department of Health recently described in its new IT Strategy (The Power of Information) as ''the solid foundations [the Department of Health] have to build upon … providing one of the most successfully and universally computerised primary care systems in the world and national information flows that are the envy of many [other] developed countries'."
CONT EMIS Group plc ("EMIS Group" or "the Group"), the UK's leading supplier of clinical software and related services to GPs and a major software supplier to high street pharmacists, announces a trading update for the six months ended 30 June 2012. The Group intends to issue its half year results on 31 August 2012. Trading for the half year was slightly ahead of expectations. EMIS Group continues to benefit from significant and growing revenue visibility. During the first half, the roll-out of EMIS Web accelerated as expected and, at the period end, there were 747 live EMIS Web GP practices with 121 installed in June 2012. There were also 1385 unfulfilled orders for EMIS Web GP and 2753 GP practices in the Familiarisation Service. The Group also put in place the majority of the people and processes necessary to support the accelerating roll-out of EMIS Web GP with a capacity of up to circa 200 EMIS Web practices per month by September 2012. The senior management team of EMIS, the Group's clinical software arm, was augmented, including the appointments of a new Chief Operating Officer and a Chief Technology Officer. In addition, significant further development resource was added to address future opportunities within the Group's marketplace. The Group announced today the forthcoming retirement of its CFO, Phillip Woodrow. Phillip will be succeeded by Peter Southby. Peter will join the Group from ENER-G plc where he is the Group Finance Director and was formerly Group Finance Director of Augean plc. Peter will join the Group no later than mid-November 2012 and there will be an appropriate hand over period. The Group's UK market share remains strong with 36.0%* of high street pharmacies and 52.2%* of GP practices.
EMIS Group plc ("EMIS Group" or "the Group"), the UK's leading supplier of clinical software and related services to GPs and a major software supplier to high street pharmacists, announces a trading update for the six months ended 30 June 2012. The Group intends to issue its half year results on 31 August 2012. Trading for the half year was slightly ahead of expectations. EMIS Group continues to benefit from significant and growing revenue visibility. During the first half, the roll-out of EMIS Web accelerated as expected and, at the period end, there were 747 live EMIS Web GP practices with 121 installed in June 2012. There were also 1385 unfulfilled orders for EMIS Web GP and 2753 GP practices in the Familiarisation Service. The Group also put in place the majority of the people and processes necessary to support the accelerating roll-out of EMIS Web GP with a capacity of up to circa 200 EMIS Web practices per month by September 2012. The senior management team of EMIS, the Group's clinical software arm, was augmented, including the appointments of a new Chief Operating Officer and a Chief Technology Officer. In addition, significant further development resource was added to address future opportunities within the Group's marketplace. The Group announced today the forthcoming retirement of its CFO, Phillip Woodrow. Phillip will be succeeded by Peter Southby. Peter will join the Group from ENER-G plc where he is the Group Finance Director and was formerly Group Finance Director of Augean plc. Peter will join the Group no later than mid-November 2012 and there will be an appropriate hand over period. The Group's UK market share remains strong with 36.0%* of high street pharmacies and 52.2%* of GP practices.
http://www.investegate.co.uk/Article.aspx?id=201207130700035769H
EMIS Group: Merchant Securities raises target from 600p to 700p, buy rating kept.
Canaccord Genuity upgrades EMIS Group to buy, target price 619p.
what the hell is happening to the share price?!
20 December 2011 EMIS secures GP data extraction contract EMIS - the UK's leading provider of healthcare software and related services to GPs - has been awarded a six-year contract with the NHS Information Centre to develop a secure data extraction service covering all EMIS practices in England. Under the contract, EMIS will provide a data extraction service to support the new national General Practice Extraction Service (GPES) - a centrally managed system that will obtain information from GP practices across England for specific, approved purposes, using robust information governance principles to ensure patient confidentiality and privacy. EMIS, which has a majorityshare of the GP clinical systems market in the UK, is the first system supplier to sign a contract with the NHS Information Centre to help deliver GPES. The EMIS data extraction service will be developed and managed through a new division of EMIS- EMIS IQ. Tim Straughan, NHS Information Centre Chief Executive, said: "The NHS Information Centre's GPES offers huge potential for supporting improvements in the prevention, diagnosis and treatment of illness. "We are delighted that EMIS have come on board as the first GP system supplier to commit to delivering the software required by GPES to safely and securely extract and communicate primary care data. EMIS' involvement is an essential element in the arrangements we are putting in place in order to ensure the service can begin extracting and delivering the data in April 2013." Sean Riddell, Chief Executive of EMIS Group, said: "EMIS has long supported the principle of freeing up clinical data - consensually, securely and responsibly - to help improve patient care. We are therefore delighted to secure this prestigious contract. "The data extraction service will be underpinned by the highest levels of security and information governance - building on the comprehensive work that EMIS has already done in this field." EMIS will design and build a secure platform from which GPES queries will be run. The initial contract term is for three years (2012-2014), with the potential for three subsequent one-year extensions. The GPES data extraction service is the first major contract for EMIS IQ, a new division of EMIS established in summer 2011. It is headed by Matt Murphy, who joined EMIS from leading healthcare intelligence provider CHKS. Managing Director of EMIS IQ Matt Murphy said: "High-quality data is an essential part of the new NHS landscape - enabling the development of more patient-focused and cost-effective services. As the leading GP systems provider, EMIS is ideally placed to meet this need. "Our ultimate aim for the EMIS IQ division is not only to meet the operational intelligence needs of healthcare organisations - for example, through data extraction services - but also to evaluate and disseminate system-driven clinical best practice, improving patient car
Peel Hunt initiates buy on EMIS Group, target price 600p.
http://www.ehi.co.uk/news/ehi/7258/emis-web-installations-put-back Surprised no announcement to the market, no reason given to practices for cancelling deployments. No doubt more will be looking at SystmOne as an alternative now. They've been taking market share from EMIS for years now.
twice not seen that before, does it mean anything maybe only that there's a shortage of shares. Timw will tell.
to meet you both though :-)
just think I'll watch a little longer........nothing wrong withthe company its the rest of the world at the minute that's worrying!!
mannam - howdy - yes it can get lonely on these boards sometimes lol - hope all is well with you
EMIS pushing forward 02/09/2011 Ben Jaglom GP software supplier EMIS Group (EMIS) has continued its expansion across the UK, growing pre-tax profits by 31 per cent. The AIM 50 constituent reported profits of £10.2 million on sales of £35.5 million for the six months to June. Net cash increased by £2.3 million to £12.8 million while the interim dividend rose from 5.6p to 6.2p. EMIS noted that it had 53.4 per cent of the UK GP software market with 5,506 sites adding that it now hold 31 per cent of the high street pharmacy software market. The group remarked that it had managed to grow in Scotland with 117 GP practices deployed over the period in the region. Revenues from Rx Systems, the software services concern acquired last year for £10 million were also included. In an interview with Growth Company Investor chief executive Sean Ridddell enthused that the government strategy of removing primary care trusts 'plays strongly into EMIS Web' noting that 1,130 practices have ordered upgrades of the software. Looking forward Riddell pointed to further roll out in Scotland and the continued integration of Rx Systems as goals for the business. Analysts at Evolution Securities are forecasting pre-tax profits of £20.3 million (EPS: 22.4p) on sales of £74.1 million for the year to December 2011. In 2012 profits of £22.6 million (EPS: 24.2p) on turnover of £80.1 million. Recommended by Growth Company Investor last May at 377.5p and subsequently this July at 539.75p the shares currently trade at 547.5p. With some considerable growth across its key markets and with plans to benefit from proposed coalition reforms to the NHS the company represents a suitable long-term investment. Long-term buy
I'll maybe get 545p quicker than I thought!! :-)
No im watching Emis too set up an auto buy at 545p you never know your luck!!
you are on your own here LOL
Healthcare software group EMIS (EMIS) retained its "buy" rating from Evolution Securities, with a 600p target price. After a strong set of interim results the broker is confident that its forecasts are well based and believes that the company shows material organic growth potential. First half operating profits of 10.1 million pounds were 10% ahead of Evolution's expectations, and 45% higher than 2010 comparable results, due to the discontinuation of its Canadian business and a contribution of 1.1 million pounds from Rx Systems. The shares gained 22.5p to 570p